Updates are available Erratum dated 2016-04-26
Click to view Erratum: https://doi.org/10.1038/nrclinonc.2016.65
-
Authors
Khalil, Danny N.
Smith, Eric L.
Brentjens, Renier J.
Wolchok, Jedd D.
- License Information
-
More Information
Article History
First Online: 15 March 2016
Change Date: 26 April 2016
Change Type: Correction
Change Details: In the sentence "Results of a phase I trial<sup>113</sup> demonstrated that an agonist mAb targeting CD40 given as monotherapy has antitumour activity in patients with melanoma or RCC", CD40 should have read OX40. This error has been corrected in the online HTML and PDF versions of the article.
Competing interests
: D.N.K. and E.L.S. and declare no competing interests. R.J.B. is a co.founder, stockholder, and consultant for Juno Therapeutics Inc. J.D.W. is a consultant for Bristol Myers Squibb, Genentech, Medimmune, Merck Pharmaceuticals and Polynoma Pharmaceuticals.
Free to read: This content has been made available to all.
